BACKGROUND: Severe pulmonary hypertension (PH) in heart failure (HF) is a risk factor for adverse outcomes after heart transplantation (HTx). Left ventricular assist devices (LVADs) improve pulmonary hemodynamics, but our understanding of the degree of improvement and the effect on outcomes is still evolving. METHODS: We reviewed invasive pulmonary hemodynamics from 58 consecutive patients receiving LVAD support as a bridge to HTx from 1996 to 2003. The primary outcome was change in baseline transpulmonary gradient (TPG) during LVAD support and after HTx/recovery. The secondary outcome was post-HTx survival. RESULTS: All patients (age, 49 +/- 14 years, 79% male, 40% ischemic) received a pulsatile LVAD (median support, 97 days; interquartile range [IQR], 31-222). Hemodynamic measurements were obtained at baseline (median, 1 day; IQR, 1-3), during early (median, 1 day; IQR, 0-4) and late (median, 75 days; IQR, 24-186) LVAD support, and after HTx/recovery (median, 28 days; IQR, 17-40). Improvement in TPG occurred throughout LVAD support and was sustained after HTx/recovery. Levels of TPG reductions in patients with a baseline TPG in the highest quartile (14.1-26.0 mm Hg) were 8.6 +/- 3.5 vs 6.5 +/- 3.1 mm Hg in the lowest quartile (2.0-7.7 mm Hg) during LVAD support (p = 0.102), with 90% vs 100% 30-day post-HTx survival (P = 0.113). CONCLUSION: Pulmonary hemodynamics and post-HTx survival were similar after pulsatile LVAD support in patients with and without pre-implant PH. LVAD support may be a useful strategy to reverse PH in carefully selected patients, thus improving candidacy for HTx.
BACKGROUND: Severe pulmonary hypertension (PH) in heart failure (HF) is a risk factor for adverse outcomes after heart transplantation (HTx). Left ventricular assist devices (LVADs) improve pulmonary hemodynamics, but our understanding of the degree of improvement and the effect on outcomes is still evolving. METHODS: We reviewed invasive pulmonary hemodynamics from 58 consecutive patients receiving LVAD support as a bridge to HTx from 1996 to 2003. The primary outcome was change in baseline transpulmonary gradient (TPG) during LVAD support and after HTx/recovery. The secondary outcome was post-HTx survival. RESULTS: All patients (age, 49 +/- 14 years, 79% male, 40% ischemic) received a pulsatile LVAD (median support, 97 days; interquartile range [IQR], 31-222). Hemodynamic measurements were obtained at baseline (median, 1 day; IQR, 1-3), during early (median, 1 day; IQR, 0-4) and late (median, 75 days; IQR, 24-186) LVAD support, and after HTx/recovery (median, 28 days; IQR, 17-40). Improvement in TPG occurred throughout LVAD support and was sustained after HTx/recovery. Levels of TPG reductions in patients with a baseline TPG in the highest quartile (14.1-26.0 mm Hg) were 8.6 +/- 3.5 vs 6.5 +/- 3.1 mm Hg in the lowest quartile (2.0-7.7 mm Hg) during LVAD support (p = 0.102), with 90% vs 100% 30-day post-HTx survival (P = 0.113). CONCLUSION: Pulmonary hemodynamics and post-HTx survival were similar after pulsatile LVAD support in patients with and without pre-implant PH. LVAD support may be a useful strategy to reverse PH in carefully selected patients, thus improving candidacy for HTx.
Authors: Mandeep R Mehra; Jon Kobashigawa; Randall Starling; Stuart Russell; Patricia A Uber; Jayan Parameshwar; Paul Mohacsi; Sharon Augustine; Keith Aaronson; Mark Barr Journal: J Heart Lung Transplant Date: 2006-09 Impact factor: 10.247
Authors: Christian D Etz; Henryk A Welp; Tony D T Tjan; Andreas Hoffmeier; Ernst Weigang; Hans H Scheld; Christof Schmid Journal: Ann Thorac Surg Date: 2007-05 Impact factor: 4.330
Authors: David O Taylor; Leah B Edwards; Mark M Boucek; Elbert P Trulock; Paul Aurora; Jason Christie; Fabienne Dobbels; Axel O Rahmel; Berkeley M Keck; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2007-08 Impact factor: 10.247
Authors: G Tenderich; M M Koerner; B Stuettgen; L Hornik; N Mirow; M Morshuis; H Mannebach; K Minami; R Koerfer Journal: Transplant Proc Date: 1998-06 Impact factor: 1.066
Authors: Stefan Klotz; Frauke Wenzelburger; Joerg Stypmann; Henryk Welp; Gabriele Drees; Christof Schmid; Hans H Scheld Journal: Ann Thorac Surg Date: 2006-11 Impact factor: 4.330
Authors: Daniel Zimpfer; Philipp Zrunek; Wilfried Roethy; Martin Czerny; Heinz Schima; Leopold Huber; Michael Grimm; Angela Rajek; Ernst Wolner; Georg Wieselthaler Journal: J Thorac Cardiovasc Surg Date: 2007-03 Impact factor: 5.209
Authors: Branislav Radovancevic; Bojan Vrtovec; Cynthia D Thomas; Mihai Croitoru; Timothy J Myers; Rajko Radovancevic; Tehreen Khan; Edward K Massin; O H Frazier Journal: J Heart Lung Transplant Date: 2005-06 Impact factor: 10.247
Authors: Sacha P Salzberg; Mario L Lachat; Kai von Harbou; Gregor Zünd; Marko I Turina Journal: Eur J Cardiothorac Surg Date: 2005-02 Impact factor: 4.191
Authors: Yamini Krishnamurthy; Lauren B Cooper; Kishan S Parikh; G Michael Felker; Carmelo A Milano; Joseph G Rogers; Adrian F Hernandez; Chetan B Patel Journal: ASAIO J Date: 2016 Sep-Oct Impact factor: 2.872
Authors: Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Barry A Borlaug; Mihai Gheorghiade; Javed Butler Journal: Circ Heart Fail Date: 2013-05 Impact factor: 8.790
Authors: Brian A Houston; Rohan J Kalathiya; Steven Hsu; Rahul Loungani; Mary E Davis; Samuel T Coffin; Nicholas Haglund; Simon Maltais; Mary E Keebler; Peter J Leary; Daniel P Judge; Gerin R Stevens; John Rickard; Chris M Sciortino; Glenn J Whitman; Ashish S Shah; Stuart D Russell; Ryan J Tedford Journal: J Heart Lung Transplant Date: 2016-02-09 Impact factor: 10.247